Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to unlocking urgently needed new treatment options in mental health care, announced today the U.S. grant program recipients to ...

The precipitous fall occurred on Monday, 06/23/2025 when the stock dropped from its close at $4.63 on the previous Friday to open Monday at $3.08. It hit an interday low of $2.25, closing the hectic ...

Compass Pathways has selected five U.S. organizations to receive grants for developing healthcare provider training programs ...

Fluence, a leading provider of professional education in psychedelic therapy, today announced that it has been selected by Compass Pathways plc (Nasdaq: CMPS) as a recipient of its U.S. healthcare ...

COMPASS Pathways plc is a London based clinical-stage biopharmaceutical concern focused on the development of psychedelics for the treatment of mental health conditions. The company is advancing the ...

On Tuesday, Compass said it will debut a U.S. doctor education campaign, “Change the Tune in TRD,” at Psych Congress in New ...

Compass Pathways (CMPS) stock reversed steep losses and closed in the green after reporting positive test results for its psychedelic-based approach to treatment-resistant depression. The treatment ...

Compass PathwaysCMPS stock surged Monday after President Donald Trump signed an executive order to ease the approval journey for psychedelic drugs. The order has two key elements. It provides a speedy ...

ATLANTA--Strata Mental Health Solutions, the expert-led training and implementation partner preparing clinical networks to deliver psychedelic treatments, today announced it has been awarded one of ...

LONDON & NEW YORK--(BUSINESS WIRE)-- Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation announced today it has entered ...

Could COMPASS Pathways redefine mental health treatment with its psilocybin innovations? You get the full picture on this biotech play's business, risks, and what global investors should watch. ISIN: ...

As mental health treatments evolve, COMPASS Pathways leads with psilocybin-based therapies targeting depression—does this position it for major gains ahead? For investors in the United States and ...